Drug Profile


Alternative Names: EHT 202; EHT-0202

Latest Information Update: 21 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ExonHit Therapeutics
  • Developer Diaxonhit; ExonHit Therapeutics
  • Class Antiarrhythmics; Antipsychotics; Nicotinic-acids; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; GABA A receptor modulators; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Parkinson's disease; Retinal disorders; Vascular dementia

Most Recent Events

  • 19 Dec 2012 ExonHit Therapeutics has merged with InGen Biosciences to form Diaxonhit
  • 15 Mar 2011 Etazolate is available for licensing as of 15 Mar 2011.
  • 30 Oct 2009 Efficacy & adverse events data from a phase IIa trial in Alzheimer's disease presented at the 2nd Conference of Clinical Trials on Alzheimer's Disease (CTAD-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top